Resumen
In de novo metastatic luminal breast cancer, there remains an urgent need to fill the knowledge gap about which molecular mechanisms drive de novo metastatic disease. This study is the first to explore the transcriptomic profile and tumor microenvironmental differences at baseline of patients with ER+/HER2- de novo metastatic luminal breast cancer compared to patients with early (non-metastatic) luminal breast cancer to determine which aspects of the tumor microenvironment of de novo luminal breast cancer are altered and obtain perspective of the molecular mechanisms underlying breast cancer metastasis.